Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders

Abstract

Compositions and methods for the treatment and diagnosis of cancer are disclosed.

1 - 30 . (canceled) 
     
     
         31 . A method for determining whether a patient will respond to EGFR/MEK-1 targeting therapy, comprising
 a) isolating cancer cells from said patient;   b) determining expression levels of biomarkers listed in Table 2;   c) contacting said cells with an agent that targets EGFR/MEKL-1; and   d) determining whether said agent is effective to alter the biomarker expression levels determined in step b).   
     
     
         32 . The method of  claim 31 , wherein said cancer is selected from the group consisting of colorectal cancer, HNSCC, lung cancer, pancreatic cancer, glioma, breast cancer and ovarian cancer. 
     
     
         33 . The method of  claim 31 , wherein said biomarkers comprise one or more markers selected from the group consisting of ANXA6, ARF4, ARF5, ASCL2, CD59, DIXDC1, DUSP4, DUSP6, DUSP7, FER, MATK, NEDD9, PRIAP19/SLP1, PRKACB, RAPGEF1, SC4MOL and SH2DC3. 
     
     
         34 . The method of  claim 31 , wherein said agent causes a cellular phenotype selected from the group consisting of morphological alterations, altered migratory properties, altered levels of apoptosis, altered angiogenic properties, and altered chromosomal or DNA integrity.